Status: Recruiting
A Study of XB628 Alone and in Combination With Zanzalintinib in Participants With Recurrent Advanced or Metastatic Solid Tumors
This study consists of a Dose-Escalation stage and a Dose Expansion stage. The primary purpose of the dose escalation stage is to determine the maximum tolerated dose (MTD) and/or recommended dosage(s) for expansion (RDE\[s\]); and the dose expansion stage is to evaluate the preliminary antitumor activity of XB628 as a single agent and in combination with zanzalintinib.
Participants needed: 303
Trial details
Phase: Phase 1Age: 18+Biological sex: AllType: InterventionalSponsor: ExelixisUpdated: Jun 24, 2026Locations: 11
Eligibility criteria
Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1. [+7]
Primary brain tumors or known active brain metastases. [+4]